Patents by Inventor Dennis KIRCHHOFF
Dennis KIRCHHOFF has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11964953Abstract: The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: September 14, 2022Date of Patent: April 23, 2024Assignees: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert Schmees, Ulrike Roehn, Dennis Kirchhoff, Kirstin Petersen, Mareike Grees, Nicolas Werbeck, Benjamin Bader, Rienk Offringa, Corinna Link
-
Publication number: 20230399411Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: June 16, 2023Publication date: December 14, 2023Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH
-
Publication number: 20230338559Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.Type: ApplicationFiled: March 10, 2023Publication date: October 26, 2023Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER
-
Publication number: 20230167078Abstract: The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: April 20, 2021Publication date: June 1, 2023Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Ulrike ROEHN, Dennis KIRCHHOFF, Kirstin PETERSEN, Thi Thanh Uyen NGUYEN, Mareike GREES, Nicolas WERBECK, Ulf BOEMER, Benjamin BADER, Detlef STOECKIGT, Dirk KOSEMUND, Rienk OFFRINGA, Corinna LINK, Katrin NOWAK-REPPEL
-
Publication number: 20230167103Abstract: The present invention covers aminothiazole compounds of general formula (I): in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: April 20, 2021Publication date: June 1, 2023Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Ulrike ROEHN, Dennis KIRCHHOFF, Kirstin PETERSEN, Thi Thanh Uyen NGUYEN, Mareike GREES, Nicolas WERBECK, Ulf BOEMER, Benjamin BADER, Detlef STOECKIGT, Rienk OFFRINGA, Corinna LINK, Giambattista TESTOLIN, Katrin NOWAK-REPPEL
-
Patent number: 11660351Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.Type: GrantFiled: December 14, 2017Date of Patent: May 30, 2023Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Beatrix Stelte-Ludwig, Dennis Kirchhoff, Lisa Dietz, Christoph Mahlert, Simone Greven, Stephan Märsch, Sandra Berndt, Anette Sommer, Stefanie Hammer
-
Publication number: 20230148194Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 24, 2020Publication date: May 11, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Lars WORTMANN, DENNIS KIRCHHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Robin Michael MEIER, Simon Anthony HERBERT, Isabel Patrizia KERSCHGENS, DIRK KOSEMUND, Rienk OFFRINGA, Mareike GREES
-
Patent number: 11643469Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: April 29, 2022Date of Patent: May 9, 2023Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Beatrix Stelte-Ludwig, Dennis Kirchhoff, Christoph Mahlert, Simone Greven, Stephan Märsch
-
Publication number: 20230139936Abstract: The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: September 14, 2022Publication date: May 4, 2023Applicants: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Ulrike ROEHN, Dennis KIRCHHOFF, Kirstin PETERSEN, Mareike GREES, Nicolas WERBECK, Benjamin BADER, Rienk OFFRINGA, Corinna LINK
-
Publication number: 20230064809Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, m, n, o and p are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 24, 2020Publication date: March 2, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert SCHMEES, Lars WORTMANN, Dennis KIRCHHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Rienk OFFRINGA
-
Publication number: 20220362392Abstract: Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.Type: ApplicationFiled: July 12, 2022Publication date: November 17, 2022Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Sandra BERNDT, Lisa DIETZ, Stephan MÄRSCH, Stefanie HAMMER
-
Patent number: 11478554Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.Type: GrantFiled: September 1, 2021Date of Patent: October 25, 2022Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Beatrix Stelte-Ludwig, Dennis Kirchhoff, Lisa Dietz, Christoph Mahlert, Simone Greven, Stephan Märsch, Sandra Berndt, Anette Sommer, Stefanie Hammer
-
Patent number: 11433140Abstract: Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.Type: GrantFiled: December 18, 2017Date of Patent: September 6, 2022Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Beatrix Stelte-Ludwig, Dennis Kirchhoff, Sandra Berndt, Lisa Dietz, Stephan Märsch, Stefanie Hammer
-
Publication number: 20220267457Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: April 29, 2022Publication date: August 25, 2022Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH
-
Publication number: 20220016258Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.Type: ApplicationFiled: September 1, 2021Publication date: January 20, 2022Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER
-
Publication number: 20210230284Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: April 8, 2021Publication date: July 29, 2021Applicant: Bayer Pharma AktiengesellschaftInventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH
-
Patent number: 11001636Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD 123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: June 8, 2017Date of Patent: May 11, 2021Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Beatrix Stelte-Ludwig, Dennis Kirchhoff, Christoph Mahlert, Simone Greven, Stephan Märsch
-
Patent number: 10744205Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: June 20, 2016Date of Patent: August 18, 2020Assignee: Bayer Pharma AktiengesellschaftInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Beatrix Stelte-Ludwig, Christoph Mahlert, Simone Greven, Stephan Märsch, Dennis Kirchhoff
-
Publication number: 20190365916Abstract: Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.Type: ApplicationFiled: December 18, 2017Publication date: December 5, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Sandra BERNDT, Lisa DIETZ, Stephan MÄRSCH, Stefanie HAMMER
-
Publication number: 20190328897Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.Type: ApplicationFiled: December 14, 2017Publication date: October 31, 2019Applicants: Bayer Pharma Aktiengesellschaft, Bayer AktiengesellschaftInventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER